Details of the Drug

General Information of Drug (ID: DMBZN7J)

Drug Name

Litifilimab

Synonyms

BIIB059

Indication

Disease Entry	ICD 11	Status	REF
Cutaneous lupus erythematosus	EB5Z	Phase 3	[1]
Systemic lupus erythematosus	4A40.0	Phase 3	[2]
------------------------------------------------------------------------------------

Drug Type

Monoclonal antibody

Cross-matching ID

Repurposed Drugs (RPD)

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
C-type lectin domain family 4 member C (CLEC4C)	TT7YT06	CLC4C_HUMAN	Not Available	[3]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	ClinicalTrials.gov (NCT05531565) A 2-Part Seamless Part A (Phase 2)/Part B (Phase 3) Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of BIIB059 in Participants With Active Subacute Cutaneous Lupus Erythematosus and/or Chronic Cutaneous Lupus Erythematosus With or Without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy (AMETHYST). U.S.National Institutes of Health.
2	ClinicalTrials.gov (NCT05352919) A Multicenter, Randomized, Dose-Blind, Phase 3 Long-Term Extension Study to Evaluate Continuous Safety and Efficacy of Litifilimab (BIIB059) in Adult Participants With Active Systemic Lupus Erythematosus. U.S.National Institutes of Health.
3	Trial of Anti-BDCA2 Antibody Litifilimab for Cutaneous Lupus Erythematosus. N Engl J Med. 2022 Jul 28;387(4):321-331.